Coya Therapeutics, Inc. (NASDAQ:COYA) CFO Purchases $12,942.00 in Stock

Coya Therapeutics, Inc. (NASDAQ:COYA) CFO David S. Snyder bought 1,800 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was bought at an average price of $7.19 per share, with a total value of $12,942.00. Following the completion of the acquisition, the chief financial officer now owns 8,800 shares in the company, valued at $63,272. This represents a 25.71 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Coya Therapeutics Price Performance

Shares of COYA stock traded down $0.43 during trading hours on Thursday, hitting $6.81. The company had a trading volume of 90,526 shares, compared to its average volume of 71,727. The stock has a market capitalization of $113.80 million, a PE ratio of -11.14 and a beta of 0.46. The company’s fifty day moving average is $7.10 and its 200 day moving average is $7.02. Coya Therapeutics, Inc. has a fifty-two week low of $4.75 and a fifty-two week high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.15. Equities analysts forecast that Coya Therapeutics, Inc. will post -1.27 earnings per share for the current year.

Institutional Trading of Coya Therapeutics

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares in the last quarter. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics in the third quarter valued at approximately $169,000. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics during the second quarter worth about $101,000. Finally, Gilbert & Cook Inc. acquired a new stake in shares of Coya Therapeutics in the 2nd quarter valued at approximately $61,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on COYA shares. Chardan Capital reaffirmed a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Monday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.